Core Insights - CanSino Biologics Inc. has been invited to the World Government Summit 2026, marking its second consecutive year as the sole global vaccine maker present at the event [1] - The company emphasizes its mission to provide innovative, high-quality, and affordable vaccines to address unmet public health needs [2] Innovation and Development - CanSinoBIO utilizes a proprietary innovation platform that allows for rapid responses to emerging public health needs, shortening R&D cycles and extending solutions across various disease areas [3] - The company launched the world's first inhaled COVID-19 vaccine in 2022, which received emergency use approval in China, and is now applying this technology to tuberculosis with a vaccine entering Phase I clinical trials in Indonesia [4] Vaccine Initiatives - CanSinoBIO's recombinant polio vaccine (VLP-Polio) is recognized by the WHO as a candidate for future polio eradication, utilizing a novel virus-like particle assembly technology that enhances biosafety [5] - The company is also developing a recombinant pneumococcal protein vaccine (PBPV), which has shown positive preliminary results in Phase I clinical trials, offering a new option for sustainable immunization in resource-limited settings [6] Global Strategy and Collaborations - CanSinoBIO has deepened its global strategy by collaborating with partners in countries such as Indonesia, Malaysia, Saudi Arabia, and Brazil to localize its innovative achievements [7] - The company aims to enhance international commercial expansion and strengthen collaborations with governments and organizations to improve vaccine accessibility [8] Regional Developments - In Indonesia, CanSinoBIO is advancing the inhaled tuberculosis vaccine and the overseas launch of Menhycia® [9] - In Saudi Arabia and the MENA region, the company is focusing on product market access and exploring joint research and localized production partnerships [9] - In Malaysia, CanSinoBIO is constructing a vaccine fill-and-finish facility and collaborating on a multivalent mRNA influenza vaccine [9]